This article is more than 5 years old. Information may no longer be current.

Aurinia initiates phase 2 trial for voclosporin ophthalmic solution in dry eye

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aurinia Pharmaceuticals is initiating a phase 2 trial of its dry eye syndrome treatment voclosporin ophthalmic solution, according to a press release.

The ocular tolerability of VOS 0.2%, a proprietary nanomicellar formulation, will be evaluated at 4 weeks in comparison to Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) in 90 patients with mild to moderate dry eye, the release said.

“Topical calcineurin inhibition is thought to be a mainstay of treatment for dry eye, and based on its unique profile, we believe that VOS has the potential to compete in the multi-billion-dollar prescription dry eye market,” Richard M. Glickman, chairman and CEO of Aurinia, said in the release. “Our goal with this program is to develop a best-in-class treatment option, and upon completion, we will look to evaluate strategic alternatives for this asset.”